Alternative designs for clinical trials in rare diseases

被引:63
作者
Abrahamyan, Lusine [1 ,2 ]
Feldman, Brian M. [3 ,4 ,5 ]
Tomlinson, George [5 ,6 ,7 ]
Faughnan, Marie E. [8 ,9 ]
Johnson, Sindhu R. [10 ,11 ,12 ]
Diamond, Ivan R.
Gupta, Samir [13 ,14 ]
机构
[1] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[2] Toronto Hlth Econ & Technol Assessment THETA Coll, Toronto, ON, Canada
[3] Univ Toronto, Pediat, Toronto, ON, Canada
[4] Univ Toronto, Fac Med, Inst Med, Toronto, ON, Canada
[5] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[6] Univ Hlth Network, Dept Med, Toronto, ON, Canada
[7] Mt Sinai Hosp, New York, NY 10029 USA
[8] Univ Toronto, St Michaels Hosp, Fac Med, Med, Toronto, ON, Canada
[9] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Toronto, ON, Canada
[10] Univ Toronto, Med, Fac Med, Toronto, ON, Canada
[11] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[12] Toronto Scleroderma Program, Toronto, ON, Canada
[13] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[14] Univ Toronto, Dept Med, Toronto, ON, Canada
关键词
rare diseases; clinical trials; cross-over studies; adaptive trial design; Bayes theorem; SURROGATE END-POINTS; 1; RANDOMIZED-TRIALS; CROSS-OVER TRIALS; SAMPLE-SIZE; N-OF-1; TRIALS; ENRICHED ENROLLMENT; MEDICAL STATISTICS; SUBGROUP ANALYSES; ADAPTIVE DESIGNS; BAYESIAN METHODS;
D O I
10.1002/ajmg.c.31533
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学];
摘要
Evidence-based medicine requires strong scientific evidence upon which to base treatment. In rare diseases, study populations are often small, and thus this evidence is difficult to accrue. Investigators, though, should be creative and develop a flexible toolkit of methods to deal with the problems inherent in the study of rare disease. This narrative review presents alternative clinical trial designs for studying treatments of rare diseases, including cross-over and n-of-1 trials, randomized placebo-phase design, enriched enrollment, randomized withdrawal design, and classes of adaptive designs. Examples of applications of these designs are presented along with their advantages and disadvantages. Additional analytical considerations such as Bayesian analysis, internal pilots, and use of biomarkers as surrogate outcomes are further discussed. A framework for selecting appropriate clinical trial design is proposed to guide investigators in the process of selecting alternative designs for rare diseases. (c) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:313 / 331
页数:19
相关论文
共 100 条
[1]
Alternative designs for clinical trials in rare diseases [J].
Abrahamyan, Lusine ;
Feldman, Brian M. ;
Tomlinson, George ;
Faughnan, Marie E. ;
Johnson, Sindhu R. ;
Diamond, Ivan R. ;
Gupta, Samir .
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2016, 172 (04) :313-331
[2]
Abrahamyan L, 2014, J POPUL THER CLIN PH, V21, pE66
[3]
Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials [J].
Abrahamyan, Lusine ;
Li, Chuan Silvia ;
Beyene, Joseph ;
Willan, Andrew R. ;
Feldman, Brian M. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (03) :286-292
[4]
Response times follow lognormal or gamma distribution in arthritis patients [J].
Abrahamyan, Lusine ;
Beyene, Joseph ;
Feng, JingYuan ;
Chon, Yun ;
Willan, Andrew R. ;
Schmeling, Heinrike ;
Horneff, Gerd ;
Keystone, Edward C. ;
Feldman, Brian M. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (12) :1363-1369
[5]
Biomarkers and surrogate endpoints [J].
Aronson, JK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) :491-494
[6]
Case studies, single-subject research, and N of 1 randomized trials - Comparisons and contrasts [J].
Backman, CL ;
Harris, SR .
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 1999, 78 (02) :170-176
[7]
Behera Madhusmita, 2007, Cancer Control, V14, P160
[8]
Bayesian clinical trials [J].
Berry, DA .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (01) :27-36
[9]
INTERNAL PILOT-STUDIES FOR ESTIMATING SAMPLE-SIZE [J].
BIRKETT, MA ;
DAY, SJ .
STATISTICS IN MEDICINE, 1994, 13 (23-24) :2455-2463
[10]
Böllert FGE, 1999, EUR RESPIR J, V13, P107